Evidence map›Paper›PMID 34529740›Full record

ArticlePLoS pathogens2021

Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.

Janna Heide, Sophia Schulte, Matin Kohsar, Thomas Theo Brehm, Marissa Herrmann, Hendrik Karsten, Matthias Marget, Sven Peine, Alexandra M Johansson, Alessandro Sette and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Human coronavirus OC43-elicited CD4Nature communications · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Janna HeideInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Sophia SchulteInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Matin KohsarInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Thomas Theo BrehmInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.ORCID 0000-0003-1737-161X
Marissa HerrmannInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.ORCID 0000-0002-5292-0795
Hendrik KarstenInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.ORCID 0000-0002-2767-0405
Matthias MargetDepartment of Transfusion Medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Sven PeineDepartment of Transfusion Medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Alexandra M JohanssonBenaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.ORCID 0000-0003-4779-4648
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, United States of America.ORCID 0000-0001-7013-2250
Marc LütgehetmannInstitute of Medical Microbiology, Virology and Hygiene, University Medical Center, Hamburg-Eppendorf, Germany.ORCID 0000-0002-9468-7944
William W KwokBenaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.ORCID 0000-0003-4843-4599
John SidneyDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, United States of America.
Julian Schulze Zur WieschInfectious Diseases Unit, I. Department of Medicine, University Medical Center, Hamburg-Eppendorf, Germany.ORCID 0000-0002-5033-1938
Universität Hamburg · DEBenaroya Research InstituteLa Jolla Institute for Immunology · USUniversity of California San Diego · US

Funding

Single-cell atlas of lung tissue-resident memory T cells reactive to upper and lower respiratory tract pathogensU19AI118626 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Bjoern Peters · 2015 to 2026
$36.7M
T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitisU19AI142742 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Alessandro Sette · 2019 to 2026
$32.8M
Project-002U19AI135817 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI LINSLEY, PETER S · 2018 to 2022
$6.8M
NIAID NIH HHS U19 AI118626NIAID NIH HHS U19 AI135817NIAID NIH HHS U19 AI142742
6 · The paper itself

Abstract

The aim of this study was to define the breadth and specificity of dominant SARS-CoV-2-specific T cell epitopes using a comprehensive set of 135 overlapping 15-mer peptides covering the SARS-CoV-2 envelope (E), membrane (M) and nucleoprotein (N) in a cohort of 34 individuals with acute (n = 10) and resolved (n = 24) COVID-19. Following short-term virus-specific in vitro cultivation, the single peptide-specific CD4+ T cell response of each patient was screened using enzyme linked immuno spot assay (ELISpot) and confirmed by single-peptide intracellular cytokine staining (ICS) for interferon-γ (IFN-γ) production. 97% (n = 33) of patients elicited one or more N, M or E-specific CD4+ T cell responses and each patient targeted on average 21.7 (range 0-79) peptide specificities. Overall, we identified 10 N, M or E-specific peptides that showed a response frequency of more than 36% and five of them showed high binding affinity to multiple HLA class II binders in subsequent in vitro HLA binding assays. Three peptides elicited CD4+ T cell responses in more than 55% of all patients, namely Mem_P30 (aa146-160), Mem_P36 (aa176-190), both located within the M protein, and Ncl_P18 (aa86-100) located within the N protein. These peptides were further defined in terms of length and HLA restriction. Based on this epitope and restriction data we developed a novel DRB*11 tetramer (Mem_aa145-164) and examined the ex vivo phenotype of SARS-CoV-2-specific CD4+ T cells in one patient. This detailed characterization of single T cell peptide responses demonstrates that SARS-CoV-2 infection universally primes a broad T cell response directed against multiple specificities located within the N, M and E structural protein.

Indexed as

Acute DiseaseAdultAgedCD4-Positive T-LymphocytesCohort StudiesCoronavirus Envelope ProteinsCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsCOVID-19Enzyme-Linked Immunospot AssayEpitopes, T-LymphocyteFemaleHumansMaleMiddle AgedPhosphoproteinsCoronavirus Envelope ProteinsCoronavirus M ProteinsCoronavirus Nucleocapsid Proteinsenvelope protein, SARS-CoV-2Epitopes, T-Lymphocytemembrane protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Matrix Proteins

Identifiers

PMID34529740
PMCPMC8445433
OpenAlexW3199731605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.